Phase III trial shows improved survival with TAS-102 in metastatic colorectal cancer refractory to standard therapies — ScienceDaily

By | July 1, 2014

source : http://www.sciencedaily.com/releases/2014/06/140628082340.htm

Leave a Reply

Your email address will not be published. Required fields are marked *